Nivolumab a New Standard of Care in Adjuvant Settings in Esophageal and Gastroesophageal Junctional Cancer Patients
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
Nivolumab a New Standard of Care in Adjuvant Settings in Esophageal and Gastroesophageal Junctional Cancer Patients ; volume:42 ; number:05 ; year:2021 ; pages:468-469
Indian journal of medical & paediatric oncology ; 42, Heft 05 (2021), 468-469
- Contributor
-
Rajappa, Senthil J.
Nusrath, Syed
- DOI
-
10.1055/s-0041-1739189
- URN
-
urn:nbn:de:101:1-2022021010524818239853
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:19 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Rajappa, Senthil J.
- Nusrath, Syed
Other Objects (12)
Epidermal Growth Factor (EGFR) copy number aberrations in esophageal and gastro-esophageal junctional carcinoma
A Cost-Effectiveness Analysis of Adjuvant Nivolumab for Patients with Resected Esophageal Cancer or Gastroesophageal Junction Cancer in France
Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses
ASO Author Reflections: Challenges in the Management of Gastroesophageal Junctional Adenocarcinoma
Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms
Population pharmacokinetics analysis of nivolumab in Asian and non-Asian patients with gastric and gastro-esophageal junction cancers
Nivolumab plus Ipilimumab, Nivolumab adjuvant : Diskussion zur Therapieentscheidung bei BRAF-mutierten Melanom Patienten
Gastroesophageal Reflux after Repair of Esophageal Atresia
Nivolumab (Melanom, adjuvant) : Addendum zum Auftrag A21-39
Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms : Update 2021
Nivolumab (Urothelkarzinom, adjuvant) : Addendum zum Auftrag A22-53 (Dossierbewertung)
Nivolumab (Urothelkarzinom, adjuvant) : Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung
Epidermal Growth Factor (EGFR) copy number aberrations in esophageal and gastro-esophageal junctional carcinoma
A Cost-Effectiveness Analysis of Adjuvant Nivolumab for Patients with Resected Esophageal Cancer or Gastroesophageal Junction Cancer in France
Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses
ASO Author Reflections: Challenges in the Management of Gastroesophageal Junctional Adenocarcinoma
Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms
Population pharmacokinetics analysis of nivolumab in Asian and non-Asian patients with gastric and gastro-esophageal junction cancers
Nivolumab plus Ipilimumab, Nivolumab adjuvant : Diskussion zur Therapieentscheidung bei BRAF-mutierten Melanom Patienten
Gastroesophageal Reflux after Repair of Esophageal Atresia
Nivolumab (Melanom, adjuvant) : Addendum zum Auftrag A21-39
Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms : Update 2021
Nivolumab (Urothelkarzinom, adjuvant) : Addendum zum Auftrag A22-53 (Dossierbewertung)
Nivolumab (Urothelkarzinom, adjuvant) : Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung
Epidermal Growth Factor (EGFR) copy number aberrations in esophageal and gastro-esophageal junctional carcinoma
A Cost-Effectiveness Analysis of Adjuvant Nivolumab for Patients with Resected Esophageal Cancer or Gastroesophageal Junction Cancer in France
Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses
ASO Author Reflections: Challenges in the Management of Gastroesophageal Junctional Adenocarcinoma
Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms
Population pharmacokinetics analysis of nivolumab in Asian and non-Asian patients with gastric and gastro-esophageal junction cancers
Nivolumab plus Ipilimumab, Nivolumab adjuvant : Diskussion zur Therapieentscheidung bei BRAF-mutierten Melanom Patienten
Gastroesophageal Reflux after Repair of Esophageal Atresia
Nivolumab (Melanom, adjuvant) : Addendum zum Auftrag A21-39
Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms : Update 2021
Nivolumab (Urothelkarzinom, adjuvant) : Addendum zum Auftrag A22-53 (Dossierbewertung)